Phio Pharmaceuticals announced its management will attend the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026, to discuss its lead cancer treatment candidate PH-762 and strategic plans. PH-762 is an INTASYL siRNA compound aimed at treating skin cancers by silencing the PD-1 gene, offering a potential non-surgical option. The company plans to update investors on clinical progress and upcoming initiatives to advance PH-762's development and value creation. This event provides insight into Phio's efforts to enhance immune response against cancer using its proprietary gene-silencing technology.
Argus Research increased its price target for NetApp to $225, citing a 13.5% potential upside from the current price of $198.18. NetApp reported strong fiscal Q1 2027 results with revenues up 29.9% to over $2 billion and non-GAAP EPS rising 66.5% to ...
New Jersey American Water received approval for rate increases that will add $68 million annually to its revenue. This funding supports over $1.4 billion in critical infrastructure upgrades, including replacing aging water mains and improving treatme...
MoneyHero Limited reported Q3 2026 earnings with an EPS of -$0.03 and revenue of $15.75 million, missing analyst estimates. The company is shifting strategy to offer more cash rewards to attract users, which has lowered immediate revenue and resulted...
Strive, Inc. has raised close to $1 billion through its SATA preferred stock to purchase 578 Bitcoin without taking on debt. SATA pays a 13% variable dividend and trades near its $100 par value, enabling Strive to issue shares steadily without diluti...
Kentucky American Water has finished replacing aging water mains in the North Limestone-Euclid-Fontaine areas of Lexington, enhancing water service reliability and fire safety. This major infrastructure project involved extensive planning and constru...
